Details
| Stereochemistry | RACEMIC |
| Molecular Formula | C20H25FN4O |
| Molecular Weight | 356.4371 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(CCN1CCN(CC1)C2=CC=C(F)C=C2)NC(=O)C3=CC=CN=C3
InChI
InChIKey=RSKQGBFMNPDPLR-UHFFFAOYSA-N
InChI=1S/C20H25FN4O/c1-16(23-20(26)17-3-2-9-22-15-17)8-10-24-11-13-25(14-12-24)19-6-4-18(21)5-7-19/h2-7,9,15-16H,8,10-14H2,1H3,(H,23,26)
| Molecular Formula | C20H25FN4O |
| Molecular Weight | 356.4371 |
| Charge | 0 |
| Count |
|
| Stereochemistry | RACEMIC |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Optical Activity | ( + / - ) |
Niaprazine is a potent and selective antagonist of 5-HT2A and alpha-1 adrenergic receptors. It was used for the treatment of sleep disturbances in children and was investigated for the treatment of sleep disorders in patients with attention-deficit hyperactivity disorder and autistic disorder.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL231 |
|||
Target ID: CHEMBL2093870 Sources: https://www.ncbi.nlm.nih.gov/pubmed/2853885 |
25.0 nM [Ki] | ||
Target ID: CHEMBL1907610 Sources: https://www.ncbi.nlm.nih.gov/pubmed/2853885 |
77.0 nM [Ki] |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Niaprazine may improve some symptoms of attention-deficit hyperactivity disorder. | 2010-04 |
|
| Drug use in children: cohort study in three European countries. | 2008-11-24 |
|
| Anxiolytics, hypnotics, and antidepressants dispensed to adolescents in a French region in 2002. | 2006-07 |
|
| Insomnia in children: when are hypnotics indicated? | 2002 |
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 19:01:49 GMT 2025
by
admin
on
Mon Mar 31 19:01:49 GMT 2025
|
| Record UNII |
R2H3YN6E3L
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
WHO-VATC |
QN05CM16
Created by
admin on Mon Mar 31 19:01:49 GMT 2025 , Edited by admin on Mon Mar 31 19:01:49 GMT 2025
|
||
|
WHO-ATC |
N05CM16
Created by
admin on Mon Mar 31 19:01:49 GMT 2025 , Edited by admin on Mon Mar 31 19:01:49 GMT 2025
|
||
|
NCI_THESAURUS |
C29756
Created by
admin on Mon Mar 31 19:01:49 GMT 2025 , Edited by admin on Mon Mar 31 19:01:49 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
m7847
Created by
admin on Mon Mar 31 19:01:49 GMT 2025 , Edited by admin on Mon Mar 31 19:01:49 GMT 2025
|
PRIMARY | Merck Index | ||
|
C021062
Created by
admin on Mon Mar 31 19:01:49 GMT 2025 , Edited by admin on Mon Mar 31 19:01:49 GMT 2025
|
PRIMARY | |||
|
CHEMBL2105141
Created by
admin on Mon Mar 31 19:01:49 GMT 2025 , Edited by admin on Mon Mar 31 19:01:49 GMT 2025
|
PRIMARY | |||
|
2817
Created by
admin on Mon Mar 31 19:01:49 GMT 2025 , Edited by admin on Mon Mar 31 19:01:49 GMT 2025
|
PRIMARY | |||
|
DB13687
Created by
admin on Mon Mar 31 19:01:49 GMT 2025 , Edited by admin on Mon Mar 31 19:01:49 GMT 2025
|
PRIMARY | |||
|
1908
Created by
admin on Mon Mar 31 19:01:49 GMT 2025 , Edited by admin on Mon Mar 31 19:01:49 GMT 2025
|
PRIMARY | |||
|
71919
Created by
admin on Mon Mar 31 19:01:49 GMT 2025 , Edited by admin on Mon Mar 31 19:01:49 GMT 2025
|
PRIMARY | |||
|
248-431-5
Created by
admin on Mon Mar 31 19:01:49 GMT 2025 , Edited by admin on Mon Mar 31 19:01:49 GMT 2025
|
PRIMARY | |||
|
DTXSID10865369
Created by
admin on Mon Mar 31 19:01:49 GMT 2025 , Edited by admin on Mon Mar 31 19:01:49 GMT 2025
|
PRIMARY | |||
|
27367-90-4
Created by
admin on Mon Mar 31 19:01:49 GMT 2025 , Edited by admin on Mon Mar 31 19:01:49 GMT 2025
|
PRIMARY | |||
|
Niaprazine
Created by
admin on Mon Mar 31 19:01:49 GMT 2025 , Edited by admin on Mon Mar 31 19:01:49 GMT 2025
|
PRIMARY | |||
|
31722
Created by
admin on Mon Mar 31 19:01:49 GMT 2025 , Edited by admin on Mon Mar 31 19:01:49 GMT 2025
|
PRIMARY | RxNorm | ||
|
SUB09218MIG
Created by
admin on Mon Mar 31 19:01:49 GMT 2025 , Edited by admin on Mon Mar 31 19:01:49 GMT 2025
|
PRIMARY | |||
|
C76943
Created by
admin on Mon Mar 31 19:01:49 GMT 2025 , Edited by admin on Mon Mar 31 19:01:49 GMT 2025
|
PRIMARY | |||
|
100000084183
Created by
admin on Mon Mar 31 19:01:49 GMT 2025 , Edited by admin on Mon Mar 31 19:01:49 GMT 2025
|
PRIMARY | |||
|
R2H3YN6E3L
Created by
admin on Mon Mar 31 19:01:49 GMT 2025 , Edited by admin on Mon Mar 31 19:01:49 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
SALT/SOLVATE -> PARENT | |||
|
|
ENANTIOMER -> RACEMATE | |||
|
|
TARGET -> INHIBITOR |
Ki
|
||
|
|
TARGET -> INHIBITOR |
Ki
|
||
|
|
ENANTIOMER -> RACEMATE |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
METABOLITE ACTIVE -> PARENT |
Identified in the urine specimens from rat (5 mg/kg, po), dog (5 mg/kg, po) and man (1 mg/kg, po).
IN-VIVO
URINE
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |